Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluconazole is a synthetic triazole antifungal agent used to treat and prevent a wide range of fungal infections. It acts by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, which is essential for converting lanosterol to ergosterol—a key component of the fungal cell membrane. This disruption impairs cell membrane formation and function, leading to inhibition of fungal growth or death. Fluconazole is effective against most Candida species (except some resistant strains), Cryptococcus neoformans, dermatophytes, and certain other fungi. It is commonly prescribed for vaginal candidiasis (yeast infection), oropharyngeal and esophageal candidiasis (thrush), systemic Candida infections including candidemia and pneumonia, cryptococcal meningitis, urinary tract infections caused by Candida species, peritonitis due to Candida infection, as well as prophylaxis in immunocompromised patients such as those undergoing bone marrow transplantation or with advanced HIV/AIDS[1][2][3][6][8]. Fluconazole can be administered orally (tablet or suspension) or intravenously[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluconazole.